Amplified antigen-specific immune responses in HIV-1 infected individuals in a double blind DNA immunization and therapy interruption trial (Q61767257)

From Wikidata

Jump to navigation Jump to search

scholarly article by L. Gudmundsdotter et al published 26 July 2011 in Vaccine

Language	Label	Description	Also known as
English	Amplified antigen-specific immune responses in HIV-1 infected individuals in a double blind DNA immunization and therapy interruption trial	scholarly article by L. Gudmundsdotter et al published 26 July 2011 in Vaccine

Statements

scholarly article

0 references

Amplified antigen-specific immune responses in HIV-1 infected individuals in a double blind DNA immunization and therapy interruption trial (English)

0 references

molecular medicine

0 references

author name string

L. Gudmundsdotter

1

0 references

B. Wahren

2

0 references

B.K. Haller

3

0 references

A. Boberg

4

0 references

U. Edbäck

5

0 references

D. Bernasconi

6

0 references

S. Buttò

7

0 references

H. Gaines

8

0 references

N. Imami

9

0 references

F. Gotch

10

0 references

F. Lori

11

0 references

J. Lisziewicz

12

0 references

E. Sandström

13

0 references

B. Hejdeman

14

0 references

L Gudmundsdotter

1

0 references

B Wahren

2

0 references

B K Haller

3

0 references

A Boberg

4

0 references

U Edbäck

5

0 references

D Bernasconi

6

0 references

S Buttò

7

0 references

H Gaines

8

0 references

N Imami

9

0 references

F Gotch

10

0 references

F Lori

11

0 references

J Lisziewicz

12

0 references

E Sandström

13

0 references

B Hejdeman

14

0 references

language of work or name

0 references

publication date

July 2011

0 references

26 July 2011

0 references

0 references

29

0 references

5558-5566

0 references

5558-66

0 references

33

0 references

Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.064

7 January 2021

Generalized immune activation as a direct result of activated CD4+ T cell killing

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.064

7 January 2021

Innate immune recognition and activation during HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.064

7 January 2021

Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. rgp160 Phase II Vaccine Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.064

7 January 2021

Enhancement of HIV Type 1 Antigen-Specific CD4+ T Cell Memory in Subjects with Chronic HIV Type 1 Infection Receiving an HIV Type 1 Immunogen.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.064

7 January 2021

T-helper-cell proliferative responses to whole-killed human immunodeficiency virus type 1 (HIV-1) and p24 antigens of different clades in HIV-1-infected subjects vaccinated with HIV-1 immunogen (Remune)

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.064

7 January 2021

Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452)

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.064

7 January 2021

HLA- and dose-dependent immunogenicity of a peptide-based HIV-1 immunotherapy candidate (Vacc-4x)

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.064

7 January 2021

DNA immunization with HIV early genes in HIV type 1-infected patients on highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.064

7 January 2021

Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.064

7 January 2021

Plasmid vaccination of stable HIV-positive subjects on antiviral treatment results in enhanced CD8 T-cell immunity and increased control of viral "blips".

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.064

7 January 2021

Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.064

7 January 2021

Therapeutic dendritic-cell vaccine for chronic HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.064

7 January 2021

Control of viral rebound through therapeutic immunization with DermaVir

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.064

7 January 2021

Persistent antibody and T cell responses induced by HIV-1 DNA vaccine delivered by electroporation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.064

7 January 2021

Epidermal injury and infection during poxvirus immunization is crucial for the generation of highly protective T cell-mediated immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.064

7 January 2021

Multigene/multisubtype HIV-1 vaccine induces potent cellular and humoral immune responses by needle-free intradermal delivery

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.064

7 January 2021

Safety of hydroxyurea in the treatment of HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.064

7 January 2021

Hydroxyurea exerts a cytostatic but not immunosuppressive effect on T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.064

7 January 2021

Viral adaptation to immune selection pressure by HLA class I-restricted CTL responses targeting epitopes in HIV frameshift sequences

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.064

7 January 2021

Effects of Human Leukocyte Antigen Class I Genetic Parameters on Clinical Outcomes and Survival after Initiation of Highly Active Antiretroviral Therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.064

7 January 2021

DNA-encoding enzymatically active HIV-1 reverse transcriptase, but not the inactive mutant, confers resistance to experimental HIV-1 challenge.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.064

7 January 2021

Interactions of single and combined human immunodeficiency virus type 1 (HIV-1) DNA vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.064

7 January 2021

Enhanced immune responses after DNA vaccination with combined envelope genes from different HIV-1 subtypes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.064

7 January 2021

Immunization of mice with the nef gene from Human Immunodeficiency Virus type 1: study of immunological memory and long-term toxicology.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.064

7 January 2021

Rational development of a stable liquid formulation for nanomedicine products

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.064

7 January 2021

DermaVir: a novel topical vaccine for HIV/AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.064

7 January 2021

Therapeutic immunization for HIV.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.064

7 January 2021

HIV-1-specific T cell precursors with high proliferative capacity correlate with low viremia and high CD4 counts in untreated individuals.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.064

7 January 2021

Transient mobilization of human immunodeficiency virus (HIV)-specific CD4 T-helper cells fails to control virus rebounds during intermittent antiretroviral therapy in chronic HIV type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.064

7 January 2021

Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.064

7 January 2021

Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.064

7 January 2021

Identifiers

10.1016/J.VACCINE.2011.01.064

0 references

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q61767257&oldid=1545551907"